The Experts below are selected from a list of 240 Experts worldwide ranked by ideXlab platform

Guan Huaimin - One of the best experts on this subject based on the ideXlab platform.

  • Effects of adenovirus-mediated vascular endothelial growth factor 165 gene on angiogenesis of pigs via Pericardial Cavity
    Journal of Zhengzhou University, 2006
    Co-Authors: Guan Huaimin
    Abstract:

    Aim: To explore the effects of adenovirus-mediated vascular endothelial growth factor 165 gene on angiogenesis of pigs via Pericardial Cavity. Methods:Twenty healthy pigs were randomly divided into two groups, experimental group(n=10) and control group(n=10). AMI model was constructed, then the intra-Pericardial injections were performed through a small incision of the abdominal wall below the xyphoid appendix using center venous catheter. The pericardium was pretreated by injecting a mixture of collagenase(1 200 U) and hyaluronidase(3 000 U). Then 2.0×109pfu Ad-VEGF165 was injected into Pericardial Cavity in experimental group, while physiological saline was injected into control group. Immunohistochemistry assay and echocardiography were carried out to evaluate the angiogenesis in the ischemic region and cardial function at the 3rd d (n=2), 7th d (n=2) and 28th d (n=6) after injection, respectively, and enzyme- linked immunoassay(ELISA) was used to investigate the local expression of Ad-VEGF165 in plasma and myocardium. Results: The peak expression of Ad-VEGF165 gene in myocardium occurred at the 7th d after the injection and decreased gradually to baseline level at the 28th d. Microvenous density and cardiac function of the experimental group significantly increased and had the advantage over the control group(at 28th d, MVD (517.00± 75.70) mm -2 vs (226.50± 54.10) mm -2, P=0.009; LVEF (72.11±5.20)% vs (55.14±4.37)%, P=0.005). Conclusion: Gene transfer of Ad-VEGF165 via Pericardial Cavity can induce VEGF protein expression and enhance angiogenesis in ischemic region and improve cardial function of patients with AMI after being pre-treated by collagenase and hyaluronidase.

Wang Jia-ning - One of the best experts on this subject based on the ideXlab platform.

  • Effects of Adenovirus-mediated Vascular Endothelial Growth Factor 165 Gene on Cardiac Function in SD Rats of Dilated Cardiomyopathy Induced by Adriamycin via Pericardial Cavity
    Journal of Yunyang Medical College, 2008
    Co-Authors: Wang Jia-ning
    Abstract:

    Objective To study the effects of adenovirus-mediated vascular endothelial growth factor 165 gene on cardiac function in SD rat model of dilated cardiomyopathy(DCM) induced by adriamycin injection via Pericardial Cavity and explore its possible mechanism.Methods SD rat model of DCM was established at a dose of 2mg/kg once a week by adriamycin intraperitoneally injected and were randomly divided into experimental group and control group.Rats in experimental group received 1.0×109 pfu Ad-VEGF 165 injections via Pericardial Cavity(VEGF group),while 0.9 % sodium choloride was injected into rats in control group(DCM group).The pericardium was pretreated by injecting a mixture of collagenase(250U)and hyaluronidase(600U).In order to evaluate the effects of Ad-VEGF 165 gene on SD rat models of DCM,transthoracic echocardiography was performed in VEGF group at 4 weeks after treatment with Ad-VEGF 165 gene injection to measure left ventricular dimensions and calculate ejection fraction.At 2 weeks after treatment,left ventricular slices of animal model were processed for histological staining and the concentration of plasma APO-1/Fas was examined with ELISA.Results Compared with the DCM group,the left ventricular ejection fraction(LVEF),body weight(BW) and heart rate(HR) were increased significantly(P0.01),the left ventricular end diastolic(LVED),diastolic dimension(DD) and systolic dimension(SD) were smaller,the fraction shortening(FS) was larger than that in DCM group(P0.05),whereas the left ventricular end systolic(LVES) in DCM rats of Ad-VEGF 165 gene injection were decreased markedly(P0.01)by transthoracic echocardiography measurement.Compared with the DCM group,the LVES and SD in Adriamycin-DCM rats with Ad-VEGF 165 injection were decreased significantly(P0.01),the LVED and DD were smaller and FS was larger(P0.05),the LVEF and HR were increased(P0.01).The levels of plasma APO-1/Fas were lower than that in DCM group.Conclusions Ad-VEGF 165 gene injection via Pericardial Cavity has therapeutic effect on animal model of dilated cardiomyopathy and is benificial to the survival of myocytes,which may relate to inhibiting myocytes apoptosis and thus offer a novel therpeutic strategy.

Xu Zhou-min - One of the best experts on this subject based on the ideXlab platform.

  • Pericardiocentensis with central vein duct and inject OK-432 into Pericardial Cavity in treatment of malignant Pericardial effusion
    Journal of Modern Oncology, 2008
    Co-Authors: Xu Zhou-min
    Abstract:

    Objective:To study the effects of pericardiocentensis with central vein duct and inject OK-432 into Pericardial Cavity in treatment of malignant Pericardial effusion. Methods: To use Seldinger puncture technique and leaded by B ultrasonic,19 patients of malignant Pericardial effusion received pericardiocentensis with Arrow central vein duct. After drainage ,5 KE OK-432 injected in Pericardial Cavity. Results: Pericardiocentensis with central vein duct have less complication,and exhaustive drainaged. OK-432 injected in Pericardial Cavity has more beneficial effect than side effect. Conclusion: Pericardiocentensis with central vein duct and inject OK-432 into Pericardial Cavity in treatment of malignant Pericardial effusion is easy and effective.

Jingfeng Wang - One of the best experts on this subject based on the ideXlab platform.

  • Pericardial application as a new route for implanting stem‐cell cardiospheres to treat myocardial infarction
    The Journal of Physiology, 2018
    Co-Authors: Jianhua Zhang, Fan Zepei, Qin Zixi, Wang Yingwei, Jia-yuan Chen, Yangxin Chen, Jingfeng Wang
    Abstract:

    Cardiospheres (CSps) are a new form of cardiac stem cells with the advantage over other stem cells for myocardial regeneration. However, direct implantation of CSps by conventional routes to treat myocardial infarction has been limited due to potential embolism. We have implanted CSps into Pericardial Cavity and systematically assessed its efficacy on myocardial infarction. Preconditioning with Pericardial fluid enhanced the activity of CSps and matrix hydrogel prolonged their viability. This shows pretransplant optimization of stem cell potency and maintenance of cell viability can be achieved with CSps. Transplantation of optimized CSps into Pericardial Cavity improved cardiac function and alleviated myocardial fibrosis in non-infarcted area, and increased myocardial cell survival and promoted angiogenesis in the infarcted area. Mechanistically, CSps were able to directly differentiate into cardiomyocytes in vivo and promoted regeneration of myocardial cells and blood vessels in the infarcted area through a paracrine effect with released growth factors in Pericardial Cavity serving as possible paracrine mediators. This is the first demonstration of direct Pericardial administration of pre-optimized CSps, and its effectiveness on myocardial infarction by functional and morphological outcomes with distinct mechanisms. These findings establish a new strategy for therapeutic myocardial regeneration to treat myocardial infarction.

Wang J - One of the best experts on this subject based on the ideXlab platform.

  • Pericardial application as a new route for implanting stem-cell cardiospheres to treat myocardial infarction
    'Wiley', 2018
    Co-Authors: Zhang J, Wu Z, Fan Z, Qin Z, Wang Y, Chen J, Wu M, Chen Y, Wu Changhao, Wang J
    Abstract:

    Cardiospheres (CSps) are a new form of cardiac stem cells with the advantage over other stem cells for myocardial regeneration. However, direct implantation of CSps by conventional routes to treat myocardial infarction has been limited due to potential embolism. We have implanted CSps into Pericardial Cavity and systematically assessed its efficacy on myocardial infarction. Preconditioning with Pericardial fluid enhanced the activity of CSps and matrix hydrogel prolonged their viability. This shows pretransplant optimization of stem cell potency and maintenance of cell viability can be achieved with CSps. Transplantation of optimized CSps into Pericardial Cavity improved cardiac function and alleviated myocardial fibrosis in non-infarcted area, and increased myocardial cell survival and promoted angiogenesis in the infarcted area. Mechanistically, CSps were able to directly differentiate into cardiomyocytes in vivo and promoted regeneration of myocardial cells and blood vessels in the infarcted area through a paracrine effect with released growth factors in Pericardial Cavity serving as possible paracrine mediators. This is the first demonstration of direct Pericardial administration of pre-optimized CSps, and its effectiveness on myocardial infarction by functional and morphological outcomes with distinct mechanisms. These findings establish a new strategy for therapeutic myocardial regeneration to treat myocardial infarction